Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Cognito Therapeutics
Cognito Therapeutics Completes Enrollment in HOPE Pivotal Study of Spectris™ AD Therapy for the Treatment of Patients with Alzheimer’s Disease
July 01, 2025
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announces Non-invasive Neuromodulation Therapy Delays Alzheimer’s Disease Progression
June 11, 2025
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announces Spectris™ Data Demonstrating Brain Structural Maintenance and Mechanism of Action in Alzheimer’s Disease at AD/PD™ 2025
April 02, 2025
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics to Present New Data on Spectris’™ Impact on Brain Structure in Alzheimer’s Disease at AD/PD 2025
March 25, 2025
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Strengthens Executive Team to Drive Next Phase of Growth and Commercialization
February 12, 2025
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announces Spectris™ Treatment Demonstrates Myelin and Synaptic Biomarker Changes in Alzheimer’s Disease
February 11, 2025
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Presents Early-Stage Cost-Effectiveness Analysis of Spectris™ Therapy in Alzheimer’s Disease at ISPOR 2024
November 19, 2024
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announces Spectris™ Treatment Demonstrates 56.4% Reduction in Alzheimer’s Disease Dependence Score with Strong Safety Profile
October 29, 2024
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Publishes Study Demonstrating Structural Brain Preservation in Alzheimer’s Disease in Frontiers in Neurology
October 16, 2024
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics to Present New Data for Spectris™ in Alzheimer’s Disease at CTAD 2024
October 07, 2024
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Appoints Christian Howell as Chief Executive Officer
August 26, 2024
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announce OVERTURE I Study Demonstrated Significant Time Savings Using Composite Measures of Function and Cognition
July 29, 2024
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announces Scientific Presentations at the Alzheimer’s Association International Conference 2024
July 08, 2024
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announces Presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024 Meeting
April 29, 2024
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announces Spectris™ Demonstrates Durable Effects on Activities of Daily Living in the OVERTURE II Study
April 15, 2024
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announces Oral Presentation at 2024 American Academy of Neurology (AAN) Annual Meeting
March 13, 2024
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announces Spectris™ OVERTURE OLE Study Data Supports Potential Disease Modification and Early Treatment in Alzheimer’s Disease
March 11, 2024
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics OVERTURE Clinical Trial in Alzheimer's Disease Published in Frontiers in Neurology
March 06, 2024
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announces Oral Presentation on Spectris Therapy Open-Label Study Data in Alzheimer’s Disease at AD/PD 2024
February 28, 2024
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announces First Patient Enrolled in HOPE Biomarker Study
January 23, 2024
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Phase 2 OVERTURE Study MRI Imaging Analysis Published in Journal of Alzheimer’s Disease
December 11, 2023
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics to Present at the 35th Annual Piper Sandler Healthcare Conference
November 13, 2023
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Appoints Christian Howell as Chief Commercial Officer
October 30, 2023
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Presents Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety, Adherence and Durability of Treatment Benefits Over 18 Months
October 24, 2023
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics to Present Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety and Durability of Treatment Benefits Over 18 Months at CTAD 2023
October 18, 2023
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer
October 17, 2023
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Presents New MRI Data Showing Non-Invasive Gamma Stimulation Therapy Reduces Brain Atrophy and Myelin Loss in Alzheimer’s Disease
July 17, 2023
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announces Scientific Presentations at the Alzheimer’s Association International Conference 2023
June 26, 2023
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announces Poster Presentations at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2023 Meeting
May 08, 2023
From
Cognito Therapeutics
Via
Business Wire
Cognito Therapeutics Announces Key Medical and Technology Leadership Appointments as Late-Stage Neurotechnology Platform Advances
April 17, 2023
From
Cognito Therapeutics
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.